| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GPLD1 |
| Uniprot No | P80108 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-176aa |
| 氨基酸序列 | MSAFRLWPGLLIMLGSLCHRGSPCGLSTHIEIGHRALEFLQLHNGRVNYR ELLLEHQDAYQAGIVFPDCFYPSICKGGKFHDVSESTHWTPFLNASVHYI RENYPLPWEKDTEKLVAFLFGITSHMAADVSWHSLGLEQGFLRTMGAIDF HGSYSEAHSAGDFGTVYLHLLNFLVV |
| 预测分子量 | 45 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是基于GPLD1重组蛋白研究的模拟参考文献示例(注：文献为虚构，仅供格式参考)：
---
1. **"Expression and functional characterization of recombinant human GPLD1 in mammalian cells"**
*作者：Smith A, et al. (2020)*
**摘要**：本研究成功在HEK293细胞中表达并纯化了重组GPLD1蛋白，验证其水解GPI锚定蛋白的酶活性，并发现其在体外能够释放碱性磷酸酶等膜蛋白，为后续疾病模型研究奠定基础。
2. **"Recombinant GPLD1 ameliorates insulin resistance in diet-induced obese mice"**
*作者：Johnson B, et al. (2018)*
**摘要**：通过动物实验证明，重组GPLD1蛋白注射可显著改善高脂饮食小鼠的胰岛素敏感性，可能与调控肝脏脂代谢通路及减少系统性炎症相关。
3. **"Therapeutic potential of GPLD1 in neurodegenerative diseases: In vitro anti-inflammatory effects"**
*作者：Lee C, et al. (2021)*
**摘要**：体外实验显示，重组GPLD1通过调节小胶质细胞中的TLR4信号通路，抑制促炎因子释放，提示其在阿尔茨海默病等神经退行性疾病中的潜在治疗价值。
4. **"Purification and structural analysis of GPLD1: Implications for GPI-anchored protein regulation"**
*作者：Zhang Y, et al. (2019)*
**摘要**：利用大肠杆菌系统高效表达重组GPLD1.并通过X射线晶体学解析其三维结构，揭示了底物结合关键位点，为开发靶向GPLD1的调节剂提供结构基础。
---
**说明**：以上文献为示例性内容，实际研究中建议通过PubMed或Web of Science检索真实文献。如需具体文章，可提供进一步关键词或研究方向。
**Background of GPLD1 Recombinant Protein**
Glycosylphosphatidylinositol-specific phospholipase D1 (GPLD1) is a secreted enzyme primarily synthesized in the liver. It belongs to the phospholipase D superfamily and plays a critical role in cleaving glycosylphosphatidylinositol (GPI)-anchored proteins from cell membranes, releasing them into extracellular environments. This enzymatic activity regulates diverse physiological processes, including cell signaling, inflammation, and lipid metabolism. GPLD1 has garnered attention for its potential involvement in systemic metabolic homeostasis and age-related disorders.
Recombinant GPLD1 protein is engineered using biotechnological methods, often expressed in mammalian or bacterial systems to ensure proper folding and post-translational modifications. Its production enables researchers to study GPLD1’s structure-function relationships, substrate specificity, and interactions with GPI-anchored proteins in vitro. Notably, studies suggest that circulating GPLD1 levels correlate with metabolic health, and its activity may influence insulin sensitivity and neuroprotective pathways.
Recent research highlights GPLD1’s therapeutic potential. For example, animal studies demonstrate that liver-derived GPLD1 can enhance cognitive function in aged mice, possibly by modulating brain plasticity. Additionally, GPLD1 has been implicated in mitigating metabolic syndrome and inflammation, positioning it as a biomarker or therapeutic target for age-related diseases. However, its mechanisms remain incompletely understood, necessitating further exploration of its roles in health and disease. The availability of recombinant GPLD1 accelerates mechanistic studies and drug discovery efforts, offering insights into its translational applications.
×
